CO2021007830A2 - Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf - Google Patents
Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegfInfo
- Publication number
- CO2021007830A2 CO2021007830A2 CONC2021/0007830A CO2021007830A CO2021007830A2 CO 2021007830 A2 CO2021007830 A2 CO 2021007830A2 CO 2021007830 A CO2021007830 A CO 2021007830A CO 2021007830 A2 CO2021007830 A2 CO 2021007830A2
- Authority
- CO
- Colombia
- Prior art keywords
- high concentration
- antibody
- protein solution
- formulation containing
- vegf antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona anticuerpos anti-VEGF formulados como alta concentración, composiciones farmacéuticas acuosas, adecuadas para una inyección, con preferencia una inyección intravítrea. Las composiciones farmacéuticas acuosas son útiles para el suministro de una alta concentración del ingrediente activo del anticuerpo a un paciente sin altos niveles de agregación de anticuerpos y sin un alto nivel de material particulado sub-visible. Una composición acuosa de la divulgación comprende un anticuerpo que tiene una concentración de al menos 50 mg/ml. Una composición farmacéutica acuosa de la divulgación incluye un azúcar, un agente tamponador, y un surfactante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781003P | 2018-12-18 | 2018-12-18 | |
| PCT/IB2019/060859 WO2020128792A1 (en) | 2018-12-18 | 2019-12-16 | Protein solution formulation containing high concentration of an anti-vegf antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021007830A2 true CO2021007830A2 (es) | 2021-06-21 |
Family
ID=69165422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0007830A CO2021007830A2 (es) | 2018-12-18 | 2021-06-15 | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11945859B2 (es) |
| EP (1) | EP3897714A1 (es) |
| JP (2) | JP7089121B2 (es) |
| KR (1) | KR20210106476A (es) |
| CN (1) | CN113194993A (es) |
| AR (1) | AR117707A1 (es) |
| AU (1) | AU2019407063A1 (es) |
| BR (1) | BR112021011290A2 (es) |
| CA (1) | CA3119241A1 (es) |
| CL (1) | CL2021001587A1 (es) |
| CO (1) | CO2021007830A2 (es) |
| CR (1) | CR20210318A (es) |
| EC (1) | ECSP21043639A (es) |
| IL (1) | IL283456A (es) |
| JO (1) | JOP20210152A1 (es) |
| MX (1) | MX2021007393A (es) |
| PE (1) | PE20211602A1 (es) |
| SG (1) | SG11202104653XA (es) |
| TW (1) | TW202031289A (es) |
| WO (1) | WO2020128792A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| ES2687259T5 (es) | 2008-06-25 | 2022-10-14 | Novartis Ag | Anticuerpos estables y solubles que inhiben TNF |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2687259T5 (es) | 2008-06-25 | 2022-10-14 | Novartis Ag | Anticuerpos estables y solubles que inhiben TNF |
| CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| US8349322B2 (en) | 2008-06-25 | 2013-01-08 | ESBATech, an Alcon Biomedical Research Unit, LLC | Stable and soluble antibodies inhibiting VEGF |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| WO2012171987A1 (en) | 2011-06-16 | 2012-12-20 | Lonza Ltd | A process for extraction of peptides and its application in liquid phase peptide synthesis |
| AR086823A1 (es) | 2011-06-30 | 2014-01-22 | Genentech Inc | Formulaciones de anticuerpo anti-c-met, metodos |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN111867631A (zh) | 2018-03-16 | 2020-10-30 | 诺华股份有限公司 | 治疗眼部疾病的方法 |
-
2019
- 2019-12-16 CR CR20210318A patent/CR20210318A/es unknown
- 2019-12-16 AR ARP190103687A patent/AR117707A1/es unknown
- 2019-12-16 PE PE2021000916A patent/PE20211602A1/es unknown
- 2019-12-16 JO JOP/2021/0152A patent/JOP20210152A1/ar unknown
- 2019-12-16 JP JP2021534608A patent/JP7089121B2/ja active Active
- 2019-12-16 KR KR1020217021741A patent/KR20210106476A/ko unknown
- 2019-12-16 MX MX2021007393A patent/MX2021007393A/es unknown
- 2019-12-16 EP EP19836538.9A patent/EP3897714A1/en active Pending
- 2019-12-16 CN CN201980081759.8A patent/CN113194993A/zh active Pending
- 2019-12-16 CA CA3119241A patent/CA3119241A1/en active Pending
- 2019-12-16 WO PCT/IB2019/060859 patent/WO2020128792A1/en unknown
- 2019-12-16 BR BR112021011290A patent/BR112021011290A2/pt unknown
- 2019-12-16 US US16/715,580 patent/US11945859B2/en active Active
- 2019-12-16 SG SG11202104653XA patent/SG11202104653XA/en unknown
- 2019-12-16 AU AU2019407063A patent/AU2019407063A1/en active Pending
- 2019-12-16 TW TW108146070A patent/TW202031289A/zh unknown
-
2021
- 2021-05-25 IL IL283456A patent/IL283456A/en unknown
- 2021-06-15 CO CONC2021/0007830A patent/CO2021007830A2/es unknown
- 2021-06-16 EC ECSENADI202143639A patent/ECSP21043639A/es unknown
- 2021-06-16 CL CL2021001587A patent/CL2021001587A1/es unknown
-
2022
- 2022-04-20 JP JP2022069588A patent/JP2022105056A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202031289A (zh) | 2020-09-01 |
| CR20210318A (es) | 2021-07-14 |
| JOP20210152A1 (ar) | 2023-01-30 |
| AU2019407063A1 (en) | 2021-05-27 |
| ECSP21043639A (es) | 2021-07-30 |
| IL283456A (en) | 2021-07-29 |
| JP2022513253A (ja) | 2022-02-07 |
| BR112021011290A2 (pt) | 2021-11-03 |
| US20200190179A1 (en) | 2020-06-18 |
| SG11202104653XA (en) | 2021-07-29 |
| MX2021007393A (es) | 2021-09-23 |
| PE20211602A1 (es) | 2021-08-18 |
| KR20210106476A (ko) | 2021-08-30 |
| US11945859B2 (en) | 2024-04-02 |
| JP7089121B2 (ja) | 2022-06-21 |
| CN113194993A (zh) | 2021-07-30 |
| EP3897714A1 (en) | 2021-10-27 |
| CL2021001587A1 (es) | 2022-02-11 |
| JP2022105056A (ja) | 2022-07-12 |
| AR117707A1 (es) | 2021-08-25 |
| CA3119241A1 (en) | 2020-06-25 |
| WO2020128792A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201700096A (es) | Formulación estable de proteína en solución que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| JP6405406B2 (ja) | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 | |
| PE20190448A1 (es) | Formulacion farmaceutica liquida estable | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| BR112012005017B8 (pt) | Formulação farmacêutica estável e uso de uma formulação | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| JP2017531682A5 (es) | ||
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| AR117607A1 (es) | Formulaciones de anticuerpo líquidas de alta concentración | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf |